Book early and save up to $400



Metabolomics

In Drug Discovery & Development

Find the Right Targets, Improve Experimental Design & Ensure Clinical Success

18th – 20th September 2012, Boston, MA

Benefits of attending

- Hear how metabolomics is used to **improve candidate selection and reduce biological variability** by hearing cutting edge case studies from pharma and biotech
- Understand how to better use metabolomics to **validate and identify true biomarkers**
- Discover how **standardized metabolomics studies** have the potential to dramatically enhance steps in your discovery and development programs
- **Identify the most efficient way to integrate metabolomic data sets with other 'omic data** and establish a clearer picture of how the data relates to drug modality
- **Meet with the key metabolomic opinion leaders in industry and academia** to expand your network of experts and gain feedback on your own projects

Workshops: 18th September 2012

A) Assess Current Solutions in Metabolite Identification and Validation
Johan Lindberg, Associate Principal Scientist, AstraZeneca

B) Effective Statistical Modelling using Metabolomics
David Wishart, Professor, University of Alberta

Speaking companies

Pfizer · University of Alberta · Broad Institute · Netherlands Metabolomics Centre · Lilly · Merck · Harvard Medical School · Abbott – A Promise for Life · FDA · biogen idec · EMBL-EBI · Massachusetts General Hospital · Bayer · AstraZeneca

19 expert speakers including

Rick Beger
Director at the Centre of Excellence for Metabolomics
FDA

Bjoern Riefke
Head of Metabolic Profiling & Clinical Pathology
Bayer Healthcare

Thomas Roddy
Director of Analytical Chemistry
Merck

David Wishart
Professor
University of Alberta

Jeff Trimmer
Executive Director
Pfizer

Reza Salek
Scientific Investigator
European Bioinformatics Institute

Thomas Hankemeier
Director
Netherlands Metabolomic Facility

Shashi Ramaiah
Drug Safety Biomarker & Precision Medicine Lead
Pfizer

Vladimir Tolstikov
Scientist
Eli Lilly

Clary Clish
Director
Broad Institute

Tel: +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
www.metabolomics-drugdevelopment.com

hansonwade

Benefits of attending

The world's first and only pharmaceutical-focussed metabolomics meeting. Not only will you uncover and learn how to adopt best practice from drug developers using metabolomics for commercial use. You'll also find out how to fully integrate metabolomics with other 'omic data generated in drug discovery and development.

The last decade of exciting academic research in metabolomics is now being applied by drug developers to determine and validate tox and safety biomarkers. Investment from drug developers is huge as the pharmaceutical industry is now using metabolomics to **find novel targets, enhance experimental design and ensure clinical success**. However, statistical challenges and inherent variability in data sets must be overcome to realize the full potential of this exciting technology.

Metabolomics in Drug Discovery and Development is the **only** meeting where you can hear cutting edge case studies from drug developers who are already reaping the benefits of metabolomics. Attend this meeting to understand how metabolomics can be used to **reduce both costs and time in clinical development**. You will also be brought up to speed by the **FDA with the latest regulatory perspective on how to qualify biomarkers**.

Join us to hear the most innovative methods and organ specific case studies from the likes of **Pfizer, AstraZeneca and Merck**. This meeting will without question help you and your organization improve your statistical design to validate biomarkers in the data.

Attend Metabolomics in Drug Discovery and Development to:

- Listen to groundbreaking case studies on how metabolomics is being applied right now in drug discovery by **Eli Lilly, Bayer Healthcare and Biogen Idec**
- Overcome challenges in statistical analysis by listening to experts from the **European Bioinformatics Institute** and the **Netherlands Metabolomic Centre**
- Understand how **Bayer** apply metabolite profiling technology to clinical studies
- Hear how **Merck** combine metabolomic data with their existing 'omic' data sets
- Identify the current **FDA** biomarker qualification process to reduce lengthy approval processes
- Learn from **the academic leaders** as they give their perspective on how the most cutting edge research can be applied to drug discovery and development

Who should attend?

- **Pharma Companies** looking to better understand how to apply metabolomics within drug development
- **Biotechs** interested in showcasing their metabolomic research to large pharma and other drug developers
- **Not for Profit Institutes** who are interested to see how research is being applied in drug development, and who are looking for collaboration and funding opportunities
- **Service providers** specializing in metabolomic services and informatics analysis
- **Equipment Providers** offering solutions such as mass spec, nmr & chromatography

LinkedIn Search groups for: **Metabolomics in Drug Discovery and Development** to join the online community.

Hear what previous Hanson Wade attendees have to say

"Very good mix of speakers from various origins. Very valuable"
UCB Pharma

"Well organized. Far easier to network than at other events. Great job"
Biogen Idec

"An effective forum to network and learn the most recent progress on several areas"
MedImmune

"An exciting set of insightful talks on a broad array of topics"
Eli Lilly

"Very valuable, well organized, good diversity of speakers"
Daiichi-Sankyo

"Very valuable. Good mix of scientists & developers"
Boehringer-Ingelheim

Tel: +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
www.metabolomics-drugdevelopment.com

hansonwade

Keynote Session | Panel Session | Networking Session

Day 1 — 19th September 2012

8.00 **Registration**

9.00 **Chair's Opening Remarks**
Thomas Roddy, Director of Analytical Chemistry, **Merck**

9.05 **Keynote Presentation: Metabolomics and the Drug Pipeline – Where Are We Now?**
- A detailed overview of the current applications of metabolomics in drug discovery and development
- Identifying the key issues that are facing the large scale use of metabolomics
- Current outlook on the potential of metabolomics in biomarker discovery

David Wishart, Professor, **University of Alberta**

9.40 **Keynote Presentation: The FDA Biomarker Qualification Process and Current Applications of Metabolomics**
- Outline of the FDA biomarker qualification process and current usage
- The need to define 'context of use' during biomarker qualification
- Preclinical and clinical metabolomics studies of Acetaminophen

Rick Beger, Director at the Centre of Excellence for Metabolomics, **FDA**

10.15 **Speed Networking**

11.15 **Morning Refreshments**

Using Metabolomics To Identify And Validate True Biomarkers

11.50 **Combining Lipodomics and Fluxomics for Understanding Metabolic Drug Target Biology**
- Using small molecular tools to investigate the mechanism of drug action in preclinical models
- Mass spectrometry as a tool of choice for analyzing metabolites and metabolic flux
- Utilizing steady state metabolite and labelling studies to demonstrate differences in target biology and their relation to the target disease

Thomas Roddy, Director of Analytical Chemistry, **Merck**

12.25 **Application of Metabolite Profiling Technology in Toxicology and its Transition into the Clinic**
- Quantification of metabolomics effects and relation to traditional endpoints
- Using feasibility studies to detect kidney effects in the clinical environment
- Other clinical considerations for effective integration of metabolomics

Bjoern Riefke, Head of Metabolic Profiling & Clinical Pathology, **Bayer Healthcare**

1.00 **Converting High Throughput Metabolomic Data from Biofluids into Novel Biomarkers**
- Current approaches in analyzing high throughput metabolomic data
- Overview on the most current trials using metabolomic techniques
- Identifying true biomarkers in the high throughput data that can be applied directly to the pipeline

Johan Lindberg, Principal Scientist, **AstraZeneca**

1.35 **Lunch**

2.35 **Identification and Validation of Biomarkers for Nutritive Uptake**
- Using nutrition studies to identify and validate true biomarkers
- Overcome common problems involved in accurately identifying these biomarkers

Bruce Kristal, Associate Professor,
Brigan and Women's Hospital/Harvard Medical School

3.10 **Metabolomics in Toxicology: Limitations and Applications**
- Practical approaches to using metabolomics in preclinical safety studies
- Identifying metabolite imbalances in the data
- Learn how these findings can be applied to clinical trials

Paul Vancutsem, Director in Toxicology, **Biogen Idec**

3.45 **Identifying Metabolic Dependencies and Markers of Disease**
- Hear examples of metabolic dependencies in model systems
- Modelling in vivo disease state and measuring metabolic intermediates
- Understand how these results can be translated into a clinical setting

Clary Clish, Director, **Broad Institute**

4.20 **Afternoon Refreshments**

Insights Into Biological Variability And Its Effect On Drug Development

4.55 **Mapping Metabolite Fluxes to Validate Organ Specific Drug Targets**
- Understand the impact that biological variability can have when interpreting organ specific data
- Improve your understanding of how metabolomics can be used to map these effects
- Relating biological information back into target identification and validation

Nikolaos Psychogios, Research Fellow,
Massachusetts General Hospital

5.30 **Dealing with Biological Variability in Toxicological Data Interpretation**
- Understand the impact that biological variability can have when dealing with toxicological data
- Improve your understanding of how metabolomics can be used to help reduce these events

Harriet Kamendi, Scientist, **AstraZeneca**

6.05 **Chair's Closing Remarks**
Thomas Roddy, Director of Analytical Chemistry, **Merck**

5.15 **Poster Session and Refreshments**

Tel: +1 212 537 5898 **Fax: +1 212 537 5898** **Email: info@hansonwade.com**
www.metabolomics-drugdevelopment.com

hansonwade

Keynote Session | Panel Session | Networking Session

Day 2 — 20th September 2012

8.00 **Registration, Coffee & Networking**

9.00 **Chair's Opening Remarks**
Thomas Hankemeier, Director, Netherlands Metabolomic Society; **Rima Kaddurah Daouk**, Director, Pharmacometabolomics Centre

9.05 **Keynote Presentation: Implementing Pharmacometabolomics to Better Predict Patient Response**
- The importance of pharmacometabolomics to Better Predict Patient Response

Rima-Kaddurah-Daouk, Director, Pharmacometabolomics Centre

Into The Data – Challenges In Statistical Analysis Of Metabolomic Data Sets

9.40 **Keynote Presentation: Correlating Metabolomic Data 'Sets' With the 'Omic' Data for Holistic Data Sets**
- Learn how to incorporate the metabolomic data with the other 'omics' to validate results
- Effective utilization of statistical modelling can ensure you find the right information from a complex data set
- Applying an actionable hypothesis that can be incoporated

Thomas Hankemeier, Director, Netherlands Metabolomic Societye

10.15 **Morning Refreshments**

11.50 **Targeting Robust Data and Reducing Metabolomic 'White Noise'**
- Case study from Merck: How to effectively identify the relevant data and avoid pursuing false positives
- How to combine NMR/Mass Spec techniques effectively, whilst maintaining a robust data set
- Discussion on the best methods involved in finding the most robust data sets

Qiuwei Xu, Senior Research Scientist, Merck

12.25 **Integrative Methods for Analyzing Metabolomic and Genomic Data - Implications in Target Validation**
- Methods for combining genetics and metabolomics to increase our confidence that there is a causal relationship linked to disease risk
- Integration of 'omics' data to assess new target opportunities through a deeper understanding of relevant pathways and disease biology
- Case study from Pfizer CVMED Research Unit

Jeff Trimmer, Executive Director, Pfizer

1.00 **Lunch**

Standardizing The Use Of Metabolomics In Drug Development

2.00 **Improving Existing Practices to Achieve Continuity Between Labs**
- Highlight the importance of achieving continuity between different laboratories
- Identify what needs to happen in order for the field to progress efficiently

Vladimir Tolstikov, Scientist, Eli Lilly

2.35 **Panel Discussion: Strategies for Metabolomic Collaborative Studies**
- Why are more collaborative studies needed in the field?
- Identify the types of collaboration that are required
- Discussion on funding and regulatory issues

Shashi Ramaiah, Drug Safety Biomarker & Precision Medicine Lead, Pfizer
Vladamir Tolstikov, Scientist, Eli Lilly
Kathleen Smith, Principal Scientist, Biogen Idec

3.10 **Afternoon Refreshments**

3.45 **MetaboLights: A Database for Metabolomics Experiments and Derived Information**
- Using MetaboLights as a resource for raw, processed data
- Highlighting protocols for metabolomics experiments using MetaboLights
- Describing how MetaboLights allows cross-referencing between experiments

Reza Salek, Scientific Investigator, European Bioinformatics Intitute

4.20 **Panel Discussion: Practical Issues in Standardizing Metabolomic Techniques**
- Current techniques in data analysis and reporting
- Encouraging the harmonization of metabolomic techniques
- How standardizing techniques can impact drug efficacy and safety

Stormy Koeniger, Senior Research Scientist, Abbott Laboratories
Reza Salek, Scientific Investigator, European Bioinformatics Intitute
Qiuwei Xu, Senior Research Scientist, Merck

4.55 **Chair's Closing Remarks**
Thomas Hankemeier, Director, Netherlands Metabolomic Society; **Rima Kaddurah Daouk**, Director, Pharmacometabolomics Centre

Don't miss the opportunity to join our interactive pre-conference workshops

Workshop A will assess current solutions in metabolite identification and validation. Led by AstraZeneca you'll see how a leading drug company is currently using metabolomics to improve current techniques in target identification and validation with the overall aim of reducing the time and investment involved.

Workshop B is delivered by David Wishart, director of the Human Metabolome project, and will provide an unparallel insight into how you can use statistical modelling optimize metabolomics usage within your pipeline.statistical modelling optimize metabolomics usage within your pipeline.

Workshop A: Assess Current Solutions in Metabolite Identification and Validation

18th September 2012
Time: 9am – 12pm

Organisations now realize how the field of metabolomics can help their business in biomarker discovery and disease characterisation. However, there is an urgent need to improve the number of identified metabolites and the way in which they are validated.

During this workshop you will address a variety of challenges and solutions specific to metabolite identification and validation using current metabolomics techniques.

Specific focus will be placed on exploring the following issues:

- How to improve current techniques in target identification and validation
- Ways to develop a competitive advantage when applying metabolite profiling in the drug pipeline

Attend this workshop to develop effective strategies to improve identification whilst reducing the time and investment involved.

Workshop leader
Johan Lindberg
Principal Scientist
AstraZeneca

Johan obtained his PhD from Stockholm university in organic chemistry (1991). His past experience includes 5 years as an application chemist at an analytical instrument company and a further 16 years in pharmaceutical industry positions. Presently he's manager of the Molecular Profiling group within Safety Assessment/ Molecular Toxicology, AstraZeneca, Södertälje.

Current external collaborations include: Karolinska Institute, Innovative Medicines Initiative (SAFE-T), Predictive Safety Testing Consortia (PSTC), Uppsala University (MS Imaging) and Stockholm University (chemometrics).

Workshop B: Effective Statistical Modelling using Metabolomics

18th September 2012
Time: 1pm – 4pm

The ability of clinical research to set up effective statistical modelling is critical to the success of using metabolomics within the drug pipeline. However, there are key challenges with data handling that must be addressed in order to improve the efficiency and effectiveness of data sets.

This workshop will work on the development of robust statistical models to improve the validity of data sets and reduce artificial metabolite markers. You will learn:

- How to identify false positives, leading to more efficient and cost effective research
- How to conduct rigorous modelling by improving design and interpretation
- How to conduct univariate and multivariate statistics on metabolomic data to reduce following false positives

Attend this workshop to examine the key issues surrounding metabolomic data sets and how these issues can be overcome to improve experimental design and ensure clinical success.

Workshop leader
David Wishart
Professor
University of Alberta

Dr. Wishart received his BSc in 1983 in Physics from the University of Alberta and his PhD in Molecular Biophysics and Biochemistry from Yale University in 1991. A major focus of Dr. Wishart's research over the past few years has been the determination of the Human Metabolome. This multi-university effort involves using experimental and computational approaches to identify and quantify all the detectable metabolites in the human body.

This information is being archived in a freely accessible web-resource called the Human Metabolome Database (HMDB). Dr. Wishart is also developing novel methods in NMR spectroscopy, mass spectrometry, multi-dimensional chromatography and machine learning to facilitate this work.

Speakers

Rick Beger
Director at the Centre of Excellence for Metabolomics, **FDA**

Rick received his Ph.D. theoretical biophysics from Purdue University in 1991. After arriving at the NCTR, he initiated research activities using NMR-based and MS-based metabolomics methods to identify non-invasive and tissue-based metabolic biomarkers.

Clary Clish
Director
Broad Institute

Clary serves as Director of Metabolite Profiling at the Broad Institute of MIT and Harvard. Prior to joining the Broad Institute in 2008, he was Vice President, Discovery at Ore Pharmaceutics Inc. and had worked in the biotechnology industry for seven years.

Thomas Hankemeier
Director
Netherlands Metabolomic Society

Thomas is currently full professor for Analytical Biosciences at the LACDR, Leiden University and director of the Netherlands Metabolomics Centre. His research is aiming at innovative analytical tools for metabolomics-driven systems biology in personalized health strategies.

Rima Kaddurah-Daouk
Director
Pharmacometabolomics Center

Rima is one of the pioneers in the field of metabolomics and plays a leading role in its development. She established the Metabolomics Society and serves as its first president. She is also currently establishing a National Metabolomics Research Network.

Harriet Kamendi
Scientist
AstraZeneca

Harriet is a DABT certified PhD scientist with seven years experience using in vivo and in vitro approaches to characterize mechanisms of drug action with regards to both efficacy and safety. She currently works in a team consisting of multiple groups including drug metabolism and pharmacokinetics.

Stormy Koeniger
Senior Research Scientist
Abbott Laboratories

Stormy received her Ph.D. in Analytical Chemistry from Indiana University, specializimg in developing novel mass spectrometers designed to optimize bioanalytical analyses. Dr. Koeniger joined Abbott Laboratories Global Pharmaceutical Research and Development in 2006.

"Very valuable, well organized, good diversity of speakers"

Daiichi-Sankyo

Bruce Kristal
Associate Professor
Brigan and Women's Hospital/Harvard Medical School

Bruce received his PhD from Harvard University Graduate School of Arts and Sciences, Division of Medical Sciences, Committee on Virology in 1991. He is the first secretary and a member of the Board of Directors of the Metabolomics Society.

Johan Lindberg
Associate Principal Scientist
AstraZeneca

With 16 years experience from the pharmaceutical industry positions, Johan is an expert in toxicology. He is presently the manager of the Molecular Profiling group within Safety Assessment/Molecular Toxicology at AstraZeneca in Södertälje.

Nikolaos Psychogios
Research Fellow
Massachusetts General Hospital

Nikolaos is a licensed medical physicist with extended knowledge in the field of metabolomics (primarily NMR). His expertise include performing multivariate data analysis with pattern recognition techniques.

Bjoern Reifke
Associate Principal Scientist
AstraZeneca

Since 2003, Bjoern has been working in Toxicology at Bayer Healthcare in Germany. Prior to this, Bjoern was the Head of Biological Research and Development of X-ray contrast media research at Justesa Imagen in Madrid.

Shashi Ramaiah
Drug Safety Biomarker & Precision Medicine Lead
Pfizer

Shashi is currently the head of Clinical Pathology and Safety Biomarker group in Cambridge, MA and is responsible for operational and strategic aspects of safety biomarker development. Shashi is also doing a sabbatical within the Clinical Biotherapeutics.

Thomas Roddy
Director of Analytical Chemistry in Molecular Biomarkers
Merck

Tom leads the Analytical Biochemistry group in Molecular Biomarkers at Merck in NJ. He joined Merck in 2008 where he built a team to address complex biological problems by measuring lipids, metabolites, and proteins through targeted or 'omics approaches and isotope labelling studies.

Reza Salek
Scientific Investigator
European Bioinformatics Institute

Reza is a scientific investigator at the MRC HNR, Cambridge in the Lipid Profiling and Signalling group, MetaboLights Database Curator at European Bioinformatics Institute and Honorary visiting researcher at the University of Cambridge, Department of Biochemistry UK.

Kathleen Smith
Principal Scientist
Biogen Idec

As an energetic and astute leader in translational and personalized medicine, Kathleen has developed an in-depth expertise in early drug development and diagnostics in her twenty plus year career.

Vladimir Tolstikov
Scientist
Eli Lilly

Vladimir received his B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He has joined Eli Lilly and Company in 2012. He is author, contributor and participant of 45 conferences, 5 book chapters, and 48 articles.

Jeff Trimmer
Executive Director
Pfizer

Jeff currently serves as Group Leader for the Systems Biology & Whole Body Physiology and Diabetes Prevention & Remission groups. In his role he oversees a multidisciplinary group of scientists with backgrounds ranging from Molecular Biology to Applied Mathematics.

Paul Vancutsem
Director in Toxicology
Biogen Idec

Paul received his DVM, MS in genetics, and PhD in toxicology from Cornell University. Paul has over 14 years of experience in the industry and specializes in liver toxicity.

David Wishart
Professor
University of Alberta

David is cross appointed with the Department of Computing Science and the NRC's National Institute for Nanotechnology (NINT). Dr. Wishart's research interests are very broad, touching on areas relating to nanobiology, genonics, proteomics, metabolomics, bioinformatics and systems biology.

Qiuwei Xu
Senior Research Scientist
Merck

Qiuwei is an expert in NMR and Mass Spectrometry. He currently works at Merck and is heavily involved in drug discovery and analytical chemistry.

Sponsorship opportunities

Miles Harley

If your organization needs to raise profile, promote products and services or develop new partnership opportunities in the **Metabolomics** sector, contact:

tel: +44 (0)20 3141 8797
email: mharley@hansonwade.com

Working with Hanson Wade

When you work with Hanson Wade you work with a partner focused on your success. Your investment in both time and money needs to generate a return.

Our clients want that too and that's why they work with us. They want to reach a targeted audience and eliminate wastage from their marketing activities. They work with us because we deliver results. We're proud of this fact.

Our research identifies ground breaking issues and allows you to influence industry thinking at an early stage. Our expertise is recognized and respected by the industry. And our events are focused, leading edge and attended by people looking for knowledge before making decisions.

Attendee breakdown

Expected Audience Breakdown



Expected Geographical Breakdown



Hear what previous Hanson Wade sponsors have to say:

"These are relevant, well organized events with a comprehensive speaker panel featuring the key thought leaders in the industry, and an intelligent, forward thinking and discussion-provoking agenda"

QIAGEN

"The meeting allowed us time to really engage with the attendees rather than just the few minutes we might have at a tradeshow"

Lonza

"As a small company, we struggle to gain access to high-level drug development executives so the Hanson Wade meetings have been useful to make important contacts that have led to new business and partnership opportunities"

MyriadRBM

Media partners

FierceBiotech Research

Technology Networks.com Scientific Communities

MetaboNEWS

Metabolomics In Drug Discovery & Development	Boston	18th - 20th September 2012	Priority Code: MKT

Register

Online: www.metabolomics-drugdevelopment.com

Tel: +1 212 537 5898
Fax: +1 212 537 5898
Email: info@hansonwade.com

Mail: Hanson Wade
304 Park Avenue South
11th Floor, New York, NY 10010

Team discounts

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Venue and accommodation

Venue
Westin Boston Waterfront, 425 Summer Street, Boston, Massachusetts, 02210, United States.
Phone: (617) 532-4600

Accommodation
Accommodation is not included in your fee. You will be sent accommodation options upon registration.

Purchase audio presentations

If you are unable to attend the meeting in person or would like documentation in addition to your attendance you may purchase the audio recordings of the speaker presentations for **$799**.

These will be sent to you on CD rom with all available presentation slides within 10 days of the meeting. Audio orders can only be processed on receipt of credit card details.

Event prices

Package	Register and pay before: Friday 20th July*	Register and pay before: Friday 24th August*	Standard Price*
☐ Conference +2 workshops	$3197 (SAVE $400)	$3297 (SAVE $300)	$3397 (SAVE $200)
☐ Conference +1 workshop	$2698 (SAVE $300)	$2798 (SAVE $200)	$2998
☐ Conference only	$2199 (SAVE $200)	$2299 (SAVE $100)	$2399
☐ Half day workshop	$599		
Academic Rates			
☐ Conference +2 workshops	$1197		
☐ Conference +1 workshop	$898		
☐ Conference only	$599		
☐ Half day workshop	$299		

Please select your choice of workshop: Workshop A ☐ Workshop B ☐

*All discount offers (including team discounts) require payment at the time of registration to receive any discount. 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Delegate details

Title: Forename: Surname:

Job Title: Company/Organization:

Email: Direct Manager:

Address:

Postcode:

Country: Direct Telephone:

Direct Fax: Mobile:

Switchboard: Signature: Date:

Payment details

Number of delegates: ☐ Amount: $ _____ Conference Documentation: ☐ Credit Card: ☐ Visa ☐ Mastercard ☐ Amex ☐

Card No: ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐ Valid from: ☐☐/☐☐ Expiry Date: ☐☐/☐☐

Cardholders name:

Signature: Date:

Card billing address:

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ

Code: 2504

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.com

www.metabolomics-drugdevelopment.com

hansonwade